Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Phytother Res ; 36(3): 1064-1092, 2022 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-35084066

RESUMEN

The cardioprotective role of naringin has been scientifically well demonstrated in various experimental models such as diabetic cardiomyopathy, ischemic heart diseases, diet-induced cardiac injury, antihypertensive and anti-platelet activities through various mechanisms. However, there is no meta-analysis performed on the cardioprotective activity of naringin. This systematic review and meta-analysis were focused to summarize and conclude the therapeutic benefits of naringin in various cardiovascular disorders using pre-clinical evidence. The online search was performed using electronic databases such as PubMed/Medline, Scopus, ScienceDirect, and Google scholar. The search was mainly focused on the role of naringin in various cardiovascular disorders in experimental animals. Based on the inclusion and exclusion criteria 34 studies were selected. The meta-analysis revealed that naringin could significantly alleviate various physical and chemical stimuli induced cardiovascular disorders such as diabetic cardiomyopathy, ischemic heart diseases, oxidative stress-induced cardiac injury, diet-induced cardiovascular dysfunctions in experimental models involving multiple mechanisms such as antioxidant (ROS/RNS pathways), anti-inflammatory (COX-2, IL-6, TNF-α, NF-κB pathways), enhancing angiogenic factors (VEGF, VCAM, HIF-1α, iNO), suppressing the apoptotic factors (BCL-2, BAX, caspases) and modulation of PCSK-9, PKCα/ß, PPAR-α, JAK/STAT, MAPKs (p38α, ERK1/2, JNK), and PI3K/AKT/mTOR/p70S6K associated pathways. Further, these changes at the cellular and molecular levels were manifested as improvement in the structural, functional, and physiology of the heart upon the naringin treatment. In conclusion, this systematic review and meta-analysis support the available scientific evidence on the therapeutic benefits of naringin in the management of various cardiovascular conditions.


Asunto(s)
Flavanonas , Fosfatidilinositol 3-Quinasas , Animales , Flavanonas/farmacología , Flavanonas/uso terapéutico , FN-kappa B/metabolismo , Estrés Oxidativo , Fosfatidilinositol 3-Quinasas/metabolismo
2.
Inflammopharmacology ; 29(5): 1565-1577, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34365555

RESUMEN

AIMS: The objective of this study was to assess the anti-stroke activity of acteoside isolated from methanolic root extract of C. oppositifolia METHODS: Ischemia-reperfusion(I/R) brain injury was induced in Wistar rats to assess the anti-stroke activity of acteoside. Rats were pretreated with acteoside (10, 25 & 50 mg/kg, p.o.) before the induction of I/R injury. Parameters such as neurological, motor-cognitive functions were evaluated along with morphological (brain volume, infarct size), biochemical (SOD, Catalase, GSH, lipid peroxidation, TNF-α, IL-6, IL-10, ICAM-1, HIF-1α, VEGF, and NF-κB), histopathological, and gene expression studies (HIF-1α, VEGF) were performed to study the protective effect of acteoside against I/R induced brain injury. RESULTS: I/R injury caused significant deterioration of neurological (p < 0.01), motor (p < 0.01) and cognitive (p < 0.01) functions, associated with increase in the brain volume (p < 0.01), and infarct size (p < 0.01); increase in the levels of MDA, TNF-α, IL-6, ICAM-1, HIF-1α, VEGF, and NF-κB along with significant decrease in SOD, catalase, GSH, and IL-10 (p < 0.01 for all parameters) compared to Sham control group. Histology of brain tissue of disease control group exhibited significant vascular changes, neutrophil infiltration, cerebral oedema, and necrosis of the neuronal cells. Further, the gene-expression studies showed significant increase in the HIF-1α (p < 0.01) and VEGF (p < 0.01) mRNA levels in the I/R control compared to Sham control. Interestingly, the acteoside (10, 25 & 50 mg/kg) has prevented the neurological, motor and cognitive dysfunctions, along with inhibiting the morphological, biochemical, histological and gene expression changes induced by I/R-injury (p < 0.05 for 10 mg; p < 0.01 for 25 & 50 mg/kg of acteoside for all the parameters). CONCLUSION: These findings suggest that acteoside possess potent anti-stroke activity through modulation of HIF-1α, NF-κB, and VEGF pathway along with its potent antioxidant activity.


Asunto(s)
Glucósidos/farmacología , Lamiaceae/química , Fenoles/farmacología , Extractos Vegetales/farmacología , Accidente Cerebrovascular/prevención & control , Animales , Antioxidantes/administración & dosificación , Antioxidantes/aislamiento & purificación , Antioxidantes/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Glucósidos/administración & dosificación , Glucósidos/aislamiento & purificación , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Masculino , FN-kappa B/metabolismo , Fenoles/administración & dosificación , Fenoles/aislamiento & purificación , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Ratas , Ratas Wistar , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/fisiopatología , Factor A de Crecimiento Endotelial Vascular/metabolismo
3.
Zhong Xi Yi Jie He Xue Bao ; 10(6): 690-4, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22704419

RESUMEN

OBJECTIVE: Present study was aimed to evaluate the protective effect of Bresol®, a polyherbal formulation, on mast cell degranulation and histamine release from mast cells. METHODS: Mast cell-stabilizing activity of Bresol® was evaluated against compound 48/80-induced mast cell degranulation and histamine release from rat peritoneal mast cells in ex vivo conditions. RESULTS: Microscopy of the control group smears showed more of intact mast cells, with very minimum number of degranulated mast cells and negligible amount of histamine release. In contrast, incubation of mast cells with compound 48/80 caused significant degranulation of the mast cells associated with release of high concentration of histamine in the positive control group. Furthermore, Bresol® at 100 mg/L showed a significant inhibition of compound 48/80-induced mast cell degranulation. In addition, Bresol® significantly and dose-dependently inhibited compound 48/80-induced histamine release. CONCLUSION: Bresol® inhibits compound 48/80-induced mast cell degranulation and histamine release in ex vivo conditions. The present findings could be one of the non-immunological mechanism responsible for usefulness of Bresol® in various allergic conditions.


Asunto(s)
Liberación de Histamina/efectos de los fármacos , Mastocitos/efectos de los fármacos , Preparaciones de Plantas/farmacología , p-Metoxi-N-metilfenetilamina/farmacología , Animales , Degranulación de la Célula/efectos de los fármacos , Exocitosis/efectos de los fármacos , Ratas , Ratas Wistar
4.
Zhong Xi Yi Jie He Xue Bao ; 9(11): 1254-63, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22088593

RESUMEN

OBJECTIVE: The present study was undertaken to evaluate the effects of naringin on immobilization stress-induced biochemical-behavioral changes and mitochondrial dysfunction in mice. METHODS: Mice were randomized and grouped based on body weights. Respective drug treatments were given for 14 d, and on the 15th day all the animals were subjected to a 6-hour immobilization stress; then all the animals were subjected to various behavioral paradigms and were sacrificed. Various biochemical parameters and mitochondrial functions were analyzed using brain homogenate. RESULTS: The 6-hour acute immobilization stress significantly altered the behavioral (anxiety and memory) and biochemical parameters coupled with mitochondrial dysfunction in mice. Fourteen days pretreatment with naringin (50 and 100 mg/kg, per oral) significantly inhibited the behavioral and biochemical alterations and mitochondrial dysfunction caused by acute immobilization stress (P<0.05). Further, pretreatment with L-arginine (50 mg/kg, intraperitoneally), a nitric oxide precursor, reversed the protective effect of naringin (P<0.05). In addition, pretreatment with NG-nitro-L-arginine methyl ester (5 mg/kg, intraperitoneally) caused potentiation in the protective effect of naringin. CONCLUSION: These results suggest the possible involvement of nitrergic pathway in the protective effect of naringin against immobilization stress-induced behavioral, biochemical and mitochondrial dysfunctions in mice.


Asunto(s)
Encéfalo/metabolismo , Flavanonas/farmacología , Mitocondrias/metabolismo , Óxido Nítrico/metabolismo , Estrés Fisiológico , Animales , Conducta Animal , Inmovilización , Peroxidación de Lípido , Masculino , Ratones , Mitocondrias/efectos de los fármacos , Estrés Oxidativo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA